{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polio+Vaccine", "query": { "intervention": "Polio Vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polio+Vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T21:48:42.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07160244", "title": "BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Multivalent Group B streptococcus vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Infanrix hexa", "type": "BIOLOGICAL" }, { "name": "Prevenar 20", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Prevnar 20", "type": "BIOLOGICAL" }, { "name": "Infanrix", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Day", "maximum_age": "49 Years", "sex": "ALL", "summary": "1 Day to 49 Years" }, "enrollment_count": 6000, "start_date": "2025-08-25", "completion_date": "2029-03-02", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 119, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07160244" }, { "nct_id": "NCT01491893", "title": "PVSRIPO for Recurrent Glioblastoma (GBM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "GBM", "Glioblastoma", "Glioma", "Malignant Glioma" ], "interventions": [ { "name": "Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Istari Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2012-04-25", "completion_date": "2021-10-01", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01491893" }, { "nct_id": "NCT04054752", "title": "Vaccine Response With NT-I7", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Carcinoma", "Colorectal Adenocarcinoma", "Bladder Carcinoma" ], "interventions": [ { "name": "Recombinant human IL-7-hyFc (NT-I7)", "type": "BIOLOGICAL" }, { "name": "Vaccine sequence 1", "type": "BIOLOGICAL" }, { "name": "Vaccine sequence 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 0, "start_date": "2023-05-30", "completion_date": "2023-11-01", "has_results": false, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04054752" }, { "nct_id": "NCT00355121", "title": "Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Meningococcal Meningitis", "Tetanus", "Diphtheria", "Pertussis", "Poliomyelitis" ], "interventions": [ { "name": "Polysaccharide Diphtheria Toxoid Conjugate Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "7 Years", "sex": "ALL", "summary": "4 Years to 7 Years" }, "enrollment_count": 882, "start_date": "2006-10", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2011-08-24", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 26, "location_summary": "Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Layton, UT 84041", "state": "Georgia" }, { "city": "Bardstown", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00355121" }, { "nct_id": "NCT03564782", "title": "Examining Bioactivity of PVSRIPO in Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Invasive Breast Cancer" ], "interventions": [ { "name": "PVSRIPO", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Istari Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2019-06-30", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564782" }, { "nct_id": "NCT01129362", "title": "Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pertussis" ], "interventions": [ { "name": "Pentacel® (DTaP-IPV/Hib)", "type": "BIOLOGICAL" }, { "name": "Other Pertussis Vaccines", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "59 Months", "sex": "ALL", "summary": "Up to 59 Months" }, "enrollment_count": 1195, "start_date": "2010-02-08", "completion_date": "2014-12-30", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 2, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129362" }, { "nct_id": "NCT00505063", "title": "Prospective Trial of Vaccine Responses in Childhood Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Cancer", "Multiple Diseases" ], "interventions": [ { "name": "Immunization Schedule patients <7 years.", "type": "BIOLOGICAL" }, { "name": "Immunization Schedule patients > or = to 7 years and <11 years of age", "type": "BIOLOGICAL" }, { "name": "Immunization Schedule patients > or = to 11 years of age", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 75, "start_date": "2007-07-10", "completion_date": "2025-06-11", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505063" }, { "nct_id": "NCT04540185", "title": "A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19", "SARS (Severe Acute Respiratory Syndrome)", "SARS-CoV Infection", "SARS-CoV-2" ], "interventions": [ { "name": "Biological: oral polio vaccine", "type": "BIOLOGICAL" }, { "name": "Comparable Placebo", "type": "BIOLOGICAL" }, { "name": "NA-831", "type": "DRUG" }, { "name": "Comparable Placebo of drug", "type": "DRUG" }, { "name": "Combination of oral polio vaccine and NA-831", "type": "COMBINATION_PRODUCT" }, { "name": "Comparable Placebo of Oral Polio Vaccine and Placebo of drug", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3600, "start_date": "2020-11-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04540185" }, { "nct_id": "NCT05095844", "title": "National Vaccine Adverse Event Reporting Survey and Etiology", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19", "Vaccine Adverse Reaction", "Vaccine Reaction", "Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use", "Corona Virus Infection", "Blood Clot", "Thrombocytopenia", "Neuritis", "Vasculitis", "Influenza", "Guillain-Barré", "GWAS", "Genetic Sequencing" ], "interventions": [ { "name": "vaccinated", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Neuroganics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "5 Years to 99 Years" }, "enrollment_count": 100000, "start_date": "2022-03-15", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 1, "location_summary": "Northglenn, Colorado", "locations": [ { "city": "Northglenn", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05095844" }, { "nct_id": "NCT03922061", "title": "Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Polio" ], "interventions": [ { "name": "dmLT", "type": "BIOLOGICAL" }, { "name": "fIPV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 29, "start_date": "2019-03-19", "completion_date": "2020-06-04", "has_results": false, "last_update_posted_date": "2020-08-05", "last_synced_at": "2026-09-11T21:48:42.072Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922061" } ] }